Please use this identifier to cite or link to this item:
|Title:||Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease|
|Authors:||Sabbagh, Marwan N;Schäuble, Barbara;Anand, Keshav;Richards, Danielle;Murayama, Shigeo;Akatsu, Hiroyasu;Takao, Masaki;Rowe, Christopher C;Masters, Colin L;Barthel, Henryk;Gertz, Hermann-Josef;Peters, Oliver;Rasgon, Natalie;Jovalekic, Aleksandar;Sabri, Osama;Schulz-Schaeffer, Walter;Seibyl, John|
|Citation:||Journal of Alzheimer's Disease 2017; 56(2): 441-446|
|Abstract:||Of 57 individuals diagnosed with Alzheimer’s disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.